tbuckley/cabot-search huggingface dataset:
Digital health for the End TB Strategy: developing priority products and making them work
Authors: Dennis Falzon, Hazim Timimi, Pascal Kurosinski, Giovanni Battista Migliori, Wayne Van Gemert, Claudia Denkinger, Chris Isaacs, Alistair Story, Richard S. Garfein, Luis Gustavo do Valle Bastos, Mohammed A. Yassin, Valiantsin Rusovich, Alena Skrahina, Le Van Hoi, Tobias Broger, Ibrahim Abubakar, Andrew Hayward, Bruce V. Thomas, Zelalem Temesgen, Subhi Quraishi, Dalene von Delft, Ernesto Jaramillo, Karin Weyer, Mario C. Raviglione
Journal: European Respiratory Journal (2016)

In 2014, the World Health Organization (WHO) developed the End TB Strategy in response to a World Health Assembly Resolution requesting Member States to end the worldwide epidemic of tuberculosis (TB) by 2035. For the strategy's objectives to be realised, the next 20 years will need novel solutions to address the challenges posed by TB to health professionals, and to affected people and communities. Information and communication technology presents opportunities for innovative approaches to support TB efforts in patient care, surveillance, programme management and electronic learning. The effective application of digital health products at a large scale and their continued development need the engagement of TB patients and their caregivers, innovators, funders, policy-makers, advocacy groups, and affected communities. In April 2015, WHO established its Global Task Force on Digital Health for TB to advocate and support the development of digital health innovations in global efforts to improve TB care and prevention. We outline the group's approach to stewarding this process in alignment with the three pillars of the End TB Strategy. The supplementary material of this article includes target product profiles, as developed by early 2016, defining nine priority digital health concepts and products that are strategically positioned to enhance TB action at the country level.
Abstract B39: Long noncoding RNA PCAT14/PRCAT104; A prognostic biomarker in prostate cancer
Authors: Rohit Malik, Xiang Zhang, Sudhanshu Shukla, Yashar Y. Niknafs, Shuang Zhao, Felix Y. Feng, Arul M. Chinnaiyan
Journal: Cancer Research (2016)

Abstract Prostate cancer is the second most common epithelial cancer and the second leading cause of cancer-related death for men in the United States. While majority of prostate cancer cases are indolent and cause minimal morbidity and mortality, a subset of men progress to a hormone-refractory aggressive disease with high mortality. Markers such as PSA and PCA3 perform well in diagnosis of disease; however these biomarkers are unable to predict disease progression. Therefore, there is an urgent need to identify clinical predictors of disease progression. Long non-coding RNAs (lncRNAs) are emerging as an important class of biomolecules that exhibit significant lineage- and cancer-specificity making them ideal biomarker candidates. Using RNA-Seq data from The Cancer Genome Atlas (TCGA) and as well as from libraries generated in our laboratory, we identified PCAT14/PRCAT104 as a marker of low Gleason disease. PCAT14 was shown to be highly expressed in prostate cancer compared to benign tissue; however, its expression in prostate cancer was limited to low Gleason disease. To directly evaluate the relationship between PCAT14 levels and clinical outcome, we assessed its expression in more that 1600 Prostate cancer samples by a high-density Affymetrix GeneChip platform. In all 5 cohorts analyzed, PCAT14 was shown to be a strong prognostic marker in its ability to predict biochemical recurrence, clinical progression to systemic disease and prostate cancer–specific mortality. Furthermore, in a multivariate analysis, PCAT14 expression also predict resistance to androgen deprivation therapy (ADT) (p=0.012). More interestingly, PCAT14 was able to add to prognostic value of SCHLAP1, a lncRNA that we previously showed to be an excellent prognostic marker in prostate cancer. PCAT14 in combination with SCHLAP1 was able better in predicting 10-year metastasis free survival (AUC: 0.64) than SCHLAP1 alone (AUC=0.58). Taken together, we identified a novel marker of low grade prostate cancer that in combination with SCHALP1, a marker of aggressive cancer, can predict disease progression and hence can be of immense value for treatment individualization in prostate cancer Citation Format: Rohit Malik, Xiang Zhang, Sudhanshu Shukla, Yashar Y. Niknafs, Shuang Zhao, Felix Y. Feng, Arul M. Chinnaiyan. Long noncoding RNA PCAT14/PRCAT104; A prognostic biomarker in prostate cancer. [abstract]. In: Proceedings of the AACR Special Conference on Noncoding RNAs and Cancer: Mechanisms to Medicines ; 2015 Dec 4-7; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2016;76(6 Suppl):Abstract nr B39.
Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy
Authors: Gervasio A. Lamas, Ana Navas-Acien, Daniel B. Mark, Kerry L. Lee
Journal: Journal of the American College of Cardiology (2016)

This review summarizes evidence from 2 lines of research previously thought to be unrelated: the unexpectedly positive results of TACT (Trial to Assess Chelation Therapy), and a body of epidemiological data showing that accumulation of biologically active metals, such as lead and cadmium, is an important risk factor for cardiovascular disease. Considering these 2 areas of work together may lead to the identification of new, modifiable risk factors for atherosclerotic cardiovascular disease. We examine the history of chelation up through the report of TACT. We then describe work connecting higher metal levels in the body with the future risk of cardiovascular disease. We conclude by presenting a brief overview of a newly planned National Institutes of Health trial, TACT2, in which we will attempt to replicate the findings of TACT and to establish that removal of toxic metal stores from the body is a plausible mechanistic explanation for the benefits of edetate disodium treatment.
Propranolol
Authors: David G. Shand
Journal: New England Journal of Medicine (1975)

IT is almost 10 years since the beta-adrenergic blocking drugs were reviewed in the pages of this journal.1 Although the clinical indications for the administration of propranolol have changed surprisingly little, it has taken some time for its use to become firmly established. It is now officially approved for use in sinus tachycardia, arrhythmias and obstructive cardiomyopathy and, more recently, in the treatment of angina pectoris. The addition of this last indication and the known antihypertensive effects of propranolol, which are at present under review, make it likely that the drug will enjoy more widespread application in the United States. . . .
Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments In Patients with Relapsed or Refractory Multiple Myeloma: Evaluation of Peripheral Neuropathy In the First 1,011 Patients
Authors: Michel Delforge, Igor W. Blau, Miguel T. Hernandez, Roman Hajek, Luciano Masini, Henk Lokhorst, Giacinto La Verde, Laurence Sanhes, Javier De La Rubia, Janine Collins, Barbara Rosettani, Nancy A Brandenburg, Renato Zambello
Journal: Blood (2010)
FRI0011 IL-10-Producing Regulatory B Cells are Decreased in Systemic Sclerosis
Authors: A. Mavropoulos, T. Simopoulou, A. Varna, C. Liaskos, C. Katsiari, D. Bogdanos, L. Sakkas
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Systemic sclerosis (SSc) is a characterized by extensive fibrosis and a plethora of autoantibodies, the latter being indicative of breakage of tolerance. Regulatory B cells (Bregs) producing interleukin (IL)-10 play a significant role in suppressing inflammatory immune responses and preventing autoimmunity <h3>Objectives</h3> To investigate the significance of IL-10-producing Bregs in SSc <h3>Methods</h3> The study groups consisted of 45 patients with SSc (12 with early SSc, 33 with established SSc [of whom 16 with SSc-associated lung fibrosis,SSc-LF]) and 10 healthy controls (HCs). As a disease controls for SSc-LF, 12 patients with rheumatoid arthritis-associated LF (RA-LF) were included. Peripheral blood monunuclear cells were isolated from patients and controls. Phenotypic analysis of immature/transitional Bregs (CD19+CD24highCD38high) and memory Bregs (Cd19+CD27+Cd24high) was carried out by flow cytometry using FACS Calibur. The function of bregs was evaluated by IL-10 expression after Bcell culture with toll-like receptor (TLR)9 stimulation, and flow cytometry analysis <h3>Results</h3> Memory Bregs were decreased in early SSc (1.85±0.38), established SSc (1.6±0.88), and SSc-LF (1.52±0.17) compared to HCs (6.3±0.49, p&lt;0.001). There were more decreased in diffuse cutaneous SSc (dcSSc) than limited cutaneous SSc (lcSSc), but not significantly so. The lowest percentage of memory Bregs was in dcSSc-LF (1.36±0.16). Memory Bregs were also numerically decreased in RA-LF compared to HCs (1.58±0.26, p&lt;0.001). Transitional Bregs were also numerically decreased in early SSc, and established SSc compared to HCs (p&lt;0.02). Bregs IL-10 expression after Toll-like receptor (TLR)-9 stimulation (innate stimulus) was impaired in SSc, particularly in SSc-LF. <h3>Conclusions</h3> This is the first study to demonstrate that Bregs are reduced and functionally impaired in SSc, particularly SSc-LF. The impaired IL-10 production after innate stimulus may have clinical implications. The impairment of Bregs along with the reported increased expression of the stimulatory Bcell receptor CD19 in SSc support B cell autoaggression in SSc. These findings may offer a new therapeutic strategy for SSc, namely expanding Bregs ex-vivo and re-administering them to patients with SSc. <h3>Disclosure of Interest</h3> None declared
Resistance of Mice to Multiple Inoculations of a Transplantable Tumor
Authors: Morris K. Barrett, Walter H. Hansen
Journal: JNCI Journal of the National Cancer Institute (1954)

Resistance of Mice to Multiple Inoculations of a Transplantable Tumor Morris K. Barrett, Morris K. Barrett National Cancer Institute,2Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Walter H. Hansen Walter H. Hansen National Cancer Institute,2Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue 3, December 1954, Pages 411–420, https://doi.org/10.1093/jnci/15.3.411 Published: 01 December 1954 Article history Received: 04 August 1954 Published: 01 December 1954
Abnormal Expression and Subcellular Distribution of Subunit Proteins of the AP-3 Adaptor Complex Lead to Platelet Storage Pool Deficiency in the Pearl Mouse
Authors: Lijie Zhen, Shelley Jiang, Lijun Feng, Nicholas A. Bright, Andrew A. Peden, Albert B. Seymour, Edward K. Novak, Rosemary Elliott, Michael B. Gorin, Margaret S. Robinson, Richard T. Swank
Journal: Blood (1999)
Effect of therapeutic innovation on perception of disease and the doctor-patient relationship: a history of general paralysis of the insane and malaria fever therapy, 1910-1950
Authors: J T Braslow
Journal: American Journal of Psychiatry (1995)

The purpose of this study was to examine the effect of therapeutic innovation on the interpersonal style of physicians by using the historical example of the treatment of general paralysis of the insane by malaria fever therapy.The study employed historical qualitative and descriptive methods to analyze medical and popular literature and medical records. These medical records were from a single institution and contained verbatim transcripts of patient interviews and doctors' conferences. The author examined records of patients diagnosed with neurosyphilis from the periods before (1910-1928) and after (1928-1950) the introduction of malaria fever therapy.Before the introduction of malaria fever therapy, physicians saw their neurosyphilitic patients as "hopeless," "immoral," and "stupid" paretics--objects to be acted upon, a view consistent with the cultural belief that syphilitic patients were sinful and depraved. After the introduction of malaria fever therapy, doctors wrote more positively and empathically about their neurosyphilitic patients, allowing patients to become active participants in their therapeutic regimens. Patients with neurosyphilis voluntarily sought admission specifically for fever therapy, seeing the asylum as a place of cure rather than as an institution of confinement.This history illustrates that biological therapies can powerfully affect physicians' perceptions of patients and need not remove them from patients' subjective experiences. Instead, biological treatments may enhance physicians' ability to empathize with their patients' suffering.
Errors in Identification of 17 of 527 Brain Images in Genetic Study of Phenotypes Associated With Bipolar Disorder
Authors: Scott C. Fears, Nelson B. Freimer, Carrie E. Bearden
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Long term survival in persons with hemophilia and chronic hepatitis C: 40 year outcomes of a large single center cohort
Authors: M. Elaine Eyster, Lan Kong, Menghan Li, Ian R. Schreibman
Journal: American Journal of Hematology (2016)

We studied the course of chronic HCV infections in a cohort of 222 persons with hemophilia (PWH) and von Willebrand disease followed at our center since 1973. Twenty two (10%) developed end stage liver disease (ESLD). Forty years after HCV infection, cumulative incidence of ESLD was 12.3% and overall survival was 45.5%. Those who were infected with HCV only (n = 100) had a survival of 75.2%, while those infected with HIV (n = 122) had a survival of 24% (P < 0.001). Survivals were significantly longer for those infected with HCV at younger age (< 15 years) compared to those infected over age 30 years (P = 0.014). Cause specific deaths for ESLD and bleeding were 8.8% and 8.3% respectively. For HIV negative subjects, the annual hazard of death from ESLD and bleeding was near zero for the first 10 years, and then rose slowly over the next 20 years to 0.4/100py for ESLD and 0.2/100py for bleeding. Sixty subjects completed 79 treatment episodes. Sustained viral response rates increased from 7/21 (33%) between 1990 and 2001, to 17/29 (58%) between 2002 and 2011, and to 27/29 (93%), since 2012 with the advent of the directly acting antiviral agents. These results confirm the very slow ESLD progression rate in HIV negative PWH. However, the risk of death from both ESLD and bleeding increases steadily with longer duration of HCV infection. More aggressive surveillance to detect those with early fibrosis is needed now that curative treatment is possible in >95% of individuals. Am. J. Hematol. 91:E335-E340, 2016. © 2016 Wiley Periodicals, Inc.
Münchausen Syndrome
Authors: Ranan Rimón, Reima Kampman, Urpu Ikonen, Mauri Reunanen
Journal: Psychotherapy and Psychosomatics (1980)

In the light of the pertinent literature, 2 illustrative cases of the MÜnchausen syndrome are presented. In both patients there had been dynamically significant losses in the oedipal age leading to an intense feeling of being rejected. Both patients also exhibited problems of dependence, perfectionistic attitudes toward the self, and fear of social failure. In addition, characteristics typical of alexithymia could be noted. As a dynamical interpretation it is proposed that in these patients basic helplessness and inadequacy of expressing feelings have been channelled into multiform psychosomatic symptoms. The latter in turn have caused continuous seeking for acceptable somatic etiology and treatment of the symptoms. Thus, gradually, the clinical picture of the MÜnchausen syndrome has developed.
Abstract IA20: Chromatin looping factors and breast cancer
Authors: Aislinn Treloar, Xue Wu, Nadia Penrod, Swneke D. Bailey, Xiaoyang Zhang, Kinjal Desai, Balazs Gyorffy, Mathieu Lupien
Journal: Cancer Research (2016)

Abstract Estrogen signaling in breast cancer cells relies on chromatin interactions connecting distal regulatory elements bound by the estrogen receptor alpha (ER) to target gene promoters. This ensures stimulus and subtype-specific transcriptional responses. Chromatin looping factors, including CTCF, ZNF143 and RAD21, are genetically altered in breast cancer. However, the impact of these alterations on breast cancer development is ill defined. Here we demonstrate that ZNF143 directly regulates the formation of chromatin interactions by marking promoters connecting with distal regulatory elements. ZNF143 occupies the promoter of most early-response estrogen target genes in ER-positive breast cancer cells. Its chromatin occupancy is unaffected by estrogen stimulation suggesting that chromatin interactions are stable as opposed to modulated by stimulus. ZNF143 overexpression within ER-positive breast cancer patients associates with a worse outcome. Its loss abrogates the estrogen response in breast cancer cells. Overall, these results suggest that ZNF143 is a critical effector of the estrogen response and highlights the contribution of the chromatin looping machinery to ER-positive breast cancer development. Citation Format: Aislinn Treloar, Xue Wu, Nadia Penrod, Swneke D. Bailey, Xiaoyang Zhang, Kinjal Desai, Balazs Gyorffy, Mathieu Lupien. Chromatin looping factors and breast cancer. [abstract]. In: Proceedings of the Fourth AACR International Conference on Frontiers in Basic Cancer Research; 2015 Oct 23-26; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2016;76(3 Suppl):Abstract nr IA20.
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Nathan et al.
Authors: Edoardo Mannucci, Matteo Monami, Laura Pala, Carmen Cocca, Barbara Cresci, Gianluca Bardini, Giulio Masotti, Niccolo Marchionni, Carlo M. Rotella
Journal: Diabetes Care (2006)

Recently, a joint consensus statement by the American Diabetes Association/European Association for the Study of Diabetes (1) recommended starting insulin therapy for type 2 diabetes with basal insulin and increasing doses until a fasting glucose <130 mg/dl was obtained. The use of rapid-acting, meal-time insulin is considered only when the AlC target is not reached, despite optimal control of fasting glucose.

We observed a consecutive series of 490 outpatients (267 women and 223 men) whose type 2 diabetes was unsatisfactorily controlled (A1C ≥7%) by combined treatment with metformin and insulin secretagogues and for whom glucose self-monitoring data were available (at least four determinations after an overnight fast 2 h after breakfast in the previous month). The average of available …
Laboratory Pediatrics.
Authors: Ph Govens, P Bourdoux
Journal: JAMA (1931)

A medical department in a university hospital has 3 duties: care, teaching, and research. Partnership between the department of pediatrics and a laboratory of pediatrics is therefore essential; they are complementary. The development of the laboratory requires constructive collaboration with the medical department, clinicians addressing questions to the laboratory, and the laboratory developing tools in order to provide answers. This clearly supposes that the necessary human and material resources are made available to the laboratory. The Laboratory of Pediatrics of the ULB, through its basic activity, exists and functions, but possibilities and ambitions are broader. With the aid of the department of pediatrics and of the university, the Laboratory should be able to consolidate the diversification of its activities and financial resources, and to extent the panel of services offered.
Induction of Tumors in Rats by Tissue-Culture Preparations of SE Polyoma Virus
Authors: Eddy, Bernice E., Stewart, Sarah E., Stanton, Mearl F., Marcotte, Jerry M.
Journal: JNCI Journal of the National Cancer Institute (1959)

Journal Article Induction of Tumors in Rats by Tissue-Culture Preparations of SE Polyoma Virus Get access Bernice E. Eddy, Bernice E. Eddy Division of Biologics Standards,4 and National Cancer Institute,4Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Sarah E. Stewart, Sarah E. Stewart Division of Biologics Standards,4 and National Cancer Institute,4Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Mearl F. Stanton, Mearl F. Stanton Division of Biologics Standards,4 and National Cancer Institute,4Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Jerry M. Marcotte Jerry M. Marcotte Division of Biologics Standards,4 and National Cancer Institute,4Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 22, Issue 1, January 1959, Pages 161–171, https://doi.org/10.1093/jnci/22.1.161 Published: 01 January 1959 Article history Received: 06 October 1958 Published: 01 January 1959